Compare Carvana Co (CVNA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Twist Bioscience Corp — how do they compare? Carvana Co trades at $70.68 (market cap $79.17B), while Twist Bioscience Corp trades at $122.44 (market cap $7.72B). The key difference: Carvana Co is far larger — about 10.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| CVNA | TWST | |
|---|---|---|
Market Cap | $79.17B | $7.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $124.88 |
52-Week Low | $56.27 | $24.16 |
Enterprise Value | $81.65B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $74.20, up 4.73% today, with strong recent earnings beats and bullish technical signals. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, while net income reached a record $513 million. The stock faces valuation concerns with a P/E of 38.1 and EV/EBITDA of 575.03, but positive cash flow trends and analyst consensus support growth prospects.
The outlook remains optimistic due to robust unit growth and AI-driven cost efficiencies, though risks include profit margin compression and high debt levels. With a consensus price target of $87.18, upside potential exists if execution continues, but investors should monitor competitive pressures and macroeconomic headwinds.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
